Targeting metabotropic glutamate receptors as a new strategy against levodopa-induced dyskinesia in Parkinson's disease?

Movement Disorders

Volumn 29, Issue 6, 2014, Pages 715-719

  Picconi, Barbara ^a   Calabresi, Paolo ^a,b  

^a IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Dyskinesia; Experimental animal models; Levodopa therapy; MGluR5; Parkinson's disease

Indexed keywords

3 [(2 METHYL 4 THIAZOLYL)ETHYNYL]PYRIDINE; 4 AMINOBUTYRIC ACID; ADENOSINE A2 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENYLATE CYCLASE; AMANTADINE; CALCIUM ION; DOPAMINE 1 RECEPTOR; DOPAMINE RECEPTOR; FENOBAM; GLUTAMIC ACID; INOSITOL TRISPHOSPHATE; LEVODOPA; MAVOGLURANT; METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR 1; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3; METABOTROPIC RECEPTOR 4; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR 6; METABOTROPIC RECEPTOR 7; METABOTROPIC RECEPTOR 8; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PHOSPHOLIPASE C; PROTEIN KINASE C; ANTIPARKINSON AGENT;

AMINO TERMINAL SEQUENCE; ARTICLE; BASAL GANGLION; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CARBOXY TERMINAL SEQUENCE; CORPUS STRIATUM; DIARRHEA; DIZZINESS; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; DRUG INDUCED DISEASE; DRUG TOLERABILITY; DYSKINESIA; FATIGUE; GLOBUS PALLIDUS; HALLUCINATION; HUMAN; ILLUSION; INSOMNIA; INTERNEURON; LEVODOPA INDUCED DYSKINESIA; LONG TERM DEPRESSION; LONG TERM POTENTIATION; NERVE CELL EXCITABILITY; NERVE CELL PLASTICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN DOMAIN; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR BLOCKING; RHINOPHARYNGITIS; ANIMAL; DISEASE MODEL; DRUG EFFECTS; DYSKINESIA, DRUG-INDUCED; METABOLISM;

ANIMALS; ANTIPARKINSON AGENTS; DISEASE MODELS, ANIMAL; DYSKINESIA, DRUG-INDUCED; HUMANS; LEVODOPA; PARKINSON DISEASE; RECEPTORS, METABOTROPIC GLUTAMATE;

EID: 84899939104     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25851     Document Type: Article

References (38)

1. Cotzias GC, Papavasiliou PS, Gellene R. Modification of Parkinsonism-chronic treatment with L-dopa. N Engl J Med 1969;280:337-345.
2. Fahn S. The spectrum of levodopa-induced dyskinesias. Ann Neurol 2000;47(4 Suppl 1):S2-9; discussion, S9-S11.
3. Olanow CW, Obeso JA. Preventing levodopa-induced dyskinesias. Ann Neurol 2000;47(4 Suppl 1):S167-176; discussion, S176-S168.
4. Rascol O, Goetz C, Koller W, Poewe W, Sampaio C. Treatment interventions for Parkinson's disease: an evidence based assessment. Lancet 2002;359:1589-1598.
5. Calabresi P, Filippo MD, Ghiglieri V, Tambasco N, Picconi B. Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap. Lancet Neurol 2010;9:1106-1117.
6. Linazasoro G. New ideas on the origin of L-dopa-induced dyskinesias: age, genes and neural plasticity. Trends Pharmacol Sci 2005;26:391-397.
7. Cenci MA. L-DOPA-induced dyskinesia: cellular mechanisms and approaches to treatment. Parkinsonism Relat Disord 2007;13(Suppl 3):S263-S267.
8. Jenner P. Molecular mechanisms of L-DOPA-induced dyskinesia. Nat Rev Neurosci 2008;9:665-677.
9. Conn PJ, Battaglia G, Marino MJ, Nicoletti F. Metabotropic glutamate receptors in the basal ganglia motor circuit. Nat Rev Neurosci 2005;6:787-798.
10. Schoepp D, Bockaert J, Sladeczek F. Pharmacological and functional characteristics of metabotropic excitatory amino acid receptors. Trends Pharmacol Sci 1990;11:508-515.
11. Gubellini P, Pisani A, Centonze D, Bernardi G, Calabresi P. Metabotropic glutamate receptors and striatal synaptic plasticity: implications for neurological diseases. Prog Neurobiol 2004;74:271-300.
12. Gubellini P, Saulle E, Centonze D, et al. Selective involvement of mGlu1 receptors in corticostriatal LTD. Neuropharmacology 2001;40:839-846.
13. Gubellini P, Saulle E, Centonze D, et al. Corticostriatal LTP requires combined mGluR1 and mGluR5 activation. Neuropharmacology 2003;44:8-16.
14. Sung KW, Choi S, Lovinger DM. Activation of group I mGluRs is necessary for induction of long-term depression at striatal synapses. J Neurophysiol 2001;86:2405-2412.
15. Marino MJ, Conn PJ. Glutamate-based therapeutic approaches: allosteric modulators of metabotropic glutamate receptors. Curr Opin Pharmacol 2006;6:98-102.
16. Duty S. Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease. CNS Drugs 2012;26:1017-1032.
17. Calabresi P, Pisani A, Mercuri NB, Bernardi G. Heterogeneity of metabotropic glutamate receptors in the striatum: electrophysiological evidence. Eur J Neurosci 1993;5:1370-1377.
18. Greenamyre JT. Glutamatergic influences on the basal ganglia. Clin Neuropharmacol 2001;24:65-70.
19. Gubellini P, Picconi B, Bari M, et al. Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. J Neurosci 2002;22:6900-6907.
20. Blandini F, Armentero MT. New pharmacological avenues for the treatment of L-DOPA-induced dyskinesias in Parkinson's disease: targeting glutamate and adenosine receptors. Expert Opin Investig Drugs 2012;21:153-168.
21. Maccarrone M, Gubellini P, Bari M, et al. Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism. J Neurochem 2003;85:1018-1025.
22. Tang K, Low MJ, Grandy DK, Lovinger DM. Dopamine-dependent synaptic plasticity in striatum during in vivo development. Proc Natl Acad Sci U S A 2001;98:1255-1260.
23. Fox C, Maidment ID, Boustani M, Katona C. Memantine combined with an acetyl cholinesterase inhibitor-hope for the future? Neuropsychiatr Dis Treat 2006;2:121-125.
24. Ouattara B, Gregoire L, Morissette M, et al. Metabotropic glutamate receptor type 5 in levodopa-induced motor complications. Neurobiol Aging 2011;32:1286-1295.
25. Samadi P, Gregoire L, Morissette M, et al. mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys. Neurobiol Aging 2008;29:1040-1051.
26. Levandis G, Bazzini E, Armentero MT, Nappi G, Blandini F. Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease. Neurobiol Dis 2008;29:161-168.
27. Mela F, Marti M, Dekundy A, Danysz W, Morari M, Cenci MA. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease. J Neurochem 2007;101:483-497.
28. Rylander D, Recchia A, Mela F, Dekundy A, Danysz W, Cenci MA. Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling. J Pharmacol Exp Ther 2009;330:227-235.
29. Aubert I, Guigoni C, Li Q, et al. Enhanced preproenkephalin-B-derived opioid transmission in striatum and subthalamic nucleus converges upon globus pallidus internalis in L-3, 4-dihydroxyphenylalanine-induced dyskinesia. Biol Psychiatry 2007;61:836-844.
30. Cenci MA, Lee CS, Bjorklund A. L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur J Neurosci 1998;10:2694-2706.
31. Morin N, Gregoire L, Morissette M, et al. MPEP, an mGlu5 receptor antagonist, reduces the development of L-DOPA-induced motor complications in de novo parkinsonian monkeys: biochemical correlates. Neuropharmacology 2013;66:355-364.
32. Rylander D, Iderberg H, Li Q, et al. A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys. Neurobiol Dis 2010;39:352-361.
33. Pecknold JC, McClure DJ, Appeltauer L, Wrzesinski L, Allan T. Treatment of anxiety using fenobam (a nonbenzodiazepine) in a double-blind standard (diazepam) placebo-controlled study. J Clin Psychopharmacol 1982;2:129-133.
34. Gravius A, Dekundy A, Nagel J, More L, Pietraszek M, Danysz W. Investigation on tolerance development to subchronic blockade of mGluR5 in models of learning, anxiety, and levodopa-induced dyskinesia in rats. J Neural Transm 2008;115:1609-1619.
35. Grégoire L, Morin N, Ouattara B, et al. The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in L-Dopa-treated parkinsonian monkeys. Parkinsonism Relat Disord 2011;17:270-276.
36. Berg D, Godau J, Trenkwalder C, et al. AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials. Mov Disord 2011;26:1243-1250.
37. Stocchi F, Rascol O, Destee A, et al. AFQ056 in Parkinson patients with L-DOPA-induced dyskinesia: 13-week randomized, dose-finding study. Mov Disord.2013;28:1838-1846.
38. Cleva RM, Olive MF. Positive allosteric modulators of type 5 metabotropic glutamate receptors (mGluR5) and their therapeutic potential for the treatment of CNS disorders. Molecules 2011;16:2097-2106.